Weill Cornell Medicine in Qatar (WCM-Q) was founded in 2001 through a partnership between Cornell University and the Qatar Foundation and is the first US medical school established outside the country. WCM-Q is at the forefront of medical education, biomedical research and population health in the Middle East/North Africa (MENA) region.
WCM-Q’s research efforts empower discoveries that address unmet medical needs across the MENA region and the world, including cardiovascular disorders, metabolic syndrome (e.g., diabetes, obesity), and cancer, among others. WCM-Q faculty address these challenges by taking a holistic approach from the basic molecular, through translational research, to studies on the epidemiological level.
WCM-Q faculty have an exceptional track record of working with both academic and commercial cross-regional collaborators to produce high caliber and high impact publications that drive commercially aligned intellectual property in support of expanded industry alliances. Additionally, WCM-Q’s national cores, including miRNA, proteomics, genomics, bioinformatics, imaging and epidemiology, support deep “omic” phenotyping that is ideal for the development of precision medicines.
WCM-Q has demonstrated regional and global impact through its presence in New York City and in the MENA region. As such, WCM-Q is the global partner of choice for university-industry partnerships and is committed to achieving excellence in external partnerships. Tantamount to research excellence, Cornell’s robust administrative infrastructure centers on operational excellence in alliance and intellectual property management, with a unique ability to steer complex and cross regional projects with seamless efficiency to reach desired endpoints, and to maximize clinical outcomes.
Visit the Research Department at WCM-Q website here. For questions regarding partnering and commercializing WCM-Q related technology, contact associate director for innovation and commercialization, Mina W. Zion, at (646) 962-7058 or mwz9@cornell.edu.